List of Excipients in Branded Drug SPINRAZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Biogen Inc	SPINRAZA	nusinersen	64406-058	CALCIUM CHLORIDE	2029-03-27
Biogen Inc	SPINRAZA	nusinersen	64406-058	MAGNESIUM CHLORIDE	2029-03-27
Biogen Inc	SPINRAZA	nusinersen	64406-058	POTASSIUM CHLORIDE	2029-03-27
Biogen Inc	SPINRAZA	nusinersen	64406-058	SODIUM CHLORIDE	2029-03-27
Biogen Inc	SPINRAZA	nusinersen	64406-058	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	2029-03-27
Biogen Inc	SPINRAZA	nusinersen	64406-058	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE	2029-03-27
Biogen Inc	SPINRAZA	nusinersen	64406-058	WATER	2029-03-27

SPINRAZA Excipient Strategy and Commercial Opportunities

Last updated: September 19, 2026

Spinraza (nusinersen) is a preservative-free, ready-to-use intrathecal solution supplied in a single-dose 5 mL vial. Its excipient system is deliberately narrow: sodium chloride for tonicity, calcium chloride dihydrate, dibasic sodium phosphate, and water for injection. The commercial opportunity is therefore concentrated in sterile manufacturing, high-purity raw-material supply, container closure systems, stability support, and lifecycle formulations rather than in a broad excipient portfolio.

The product is marketed by Biogen under U.S. NDA 209531 for spinal muscular atrophy (SMA). FDA labeling identifies the product as a 12 mg/5 mL solution for intrathecal administration, with no preservative or reconstitution step.[1]

What excipients are used in SPINRAZA?

The current U.S. prescribing information lists the following formulation components:[1]

Component	Function	Commercial relevance
Nusinersen sodium	Antisense oligonucleotide active ingredient	Requires control of aggregation, degradation and adsorption
Sodium chloride	Tonicity adjustment	Commodity material, but injectable-grade quality and supply continuity are critical
Calcium chloride dihydrate	Formulation component and ionic stabilizer	Low-volume, high-purity injectable excipient
Dibasic sodium phosphate	Buffer component	Supports pH control in a narrow intrathecal formulation
Water for injection	Vehicle	Requires compliant sterile generation and validated distribution
Container closure system	Primary packaging	Important for extractables, leachables, particulate control and adsorption

The labeled quantitative composition is approximately 8.8 mg sodium chloride, 0.2 mg calcium chloride dihydrate and 0.1 mg dibasic sodium phosphate per 5 mL vial. The formulation has a near-neutral pH and is supplied as a clear, colorless solution.[1]

Why is SPINRAZA preservative-free?

Intrathecal products are administered directly into cerebrospinal fluid, which imposes tighter safety constraints than many parenteral products. Preservatives can create neurotoxicity and tolerability concerns, particularly when repeated dosing is required. Spinraza treatment involves loading doses followed by maintenance injections, so the product is supplied as a sterile, single-dose vial without antimicrobial preservatives.[1]

The absence of preservatives creates commercial demand for:

• Sterile single-use filling
• Low-bioburden raw materials
• High-integrity vial and stopper systems
• Robust aseptic processing
• Particulate and endotoxin control
• Validated hold times and shipping conditions

What is the SPINRAZA excipient strategy?

Spinraza uses a minimalist excipient strategy designed for intrathecal compatibility rather than for sensory, oral, or extended-release performance.

Tonicity control

Sodium chloride provides the primary tonicity contribution. The amount is modest compared with many intravenous products because the overall formulation must remain compatible with intrathecal administration. A supplier that offers compendial sodium chloride alone has limited differentiation. Higher-value positioning requires documented control of elemental impurities, endotoxin, particulate matter, bioburden and lot-to-lot variability.

Buffer control

Dibasic sodium phosphate is present at a very low level. This indicates that the formulation does not rely on a highly concentrated conventional buffer system. The commercial implication is that pH control, oligonucleotide stability and container interaction must be managed through the combined formulation and manufacturing process.

Potential technical risks include:

• pH drift during storage
• Oligonucleotide degradation
• Interaction with metal ions
• Surface adsorption
• Subvisible particle generation
• Sensitivity to freeze-thaw or temperature excursions

Calcium chloride as a specialized excipient

Calcium chloride dihydrate is used in a very small quantity. The ingredient is commercially available, but sterile and injectable-grade supply requires tighter controls than ordinary pharmaceutical or laboratory grades. Suppliers can differentiate through:

• Low endotoxin specifications
• Tight assay and impurity controls
• Consistent hydration state
• Metal impurity limits
• Sterile or low-bioburden supply
• Qualified global manufacturing sites

Because the quantity per vial is low, raw-material revenue is unlikely to be the main opportunity. The value lies in qualification, regulatory support and supply assurance.

What commercial opportunities exist in SPINRAZA excipients?

The strongest opportunities are downstream of the excipient itself. They include sterile manufacturing, analytical services, packaging and formulation-support technologies.

Opportunity	Attractiveness	Principal barrier
Injectable sodium chloride supply	Moderate	Price competition and broad supplier base
Pharmaceutical calcium chloride supply	Moderate	Qualification and impurity control
Dibasic sodium phosphate supply	Moderate	Limited volume and commodity pricing
Sterile fill-finish	High	Aseptic capacity and regulatory validation
Vial and stopper systems	High	Extractables, leachables and compatibility data
Oligonucleotide formulation services	High	Specialized analytical and stability capabilities
Container closure qualification	High	Product-specific validation requirements
Alternative delivery systems	High but long term	Clinical and regulatory burden
Ready-to-use intrathecal packaging	High	Human-factor and administration constraints
Generic or follow-on manufacturing	High	Patent, regulatory and manufacturing complexity

Sterile fill-finish

A contract development and manufacturing organization can capture more value by offering a fully integrated service:

1. Qualified excipient sourcing
2. Preparation of the buffered solution
3. Sterile filtration or validated aseptic processing
4. Filling into single-dose vials
5. Visual inspection and particulate testing
6. Container closure integrity testing
7. Stability and shipping qualification

Intrathecal products require a higher quality threshold than many routine injectable products. A supplier with experience in aseptic oligonucleotide fill-finish can compete on regulatory execution and batch reliability rather than on excipient price.

Primary packaging

The vial, stopper and seal are part of the product’s functional excipient strategy. The formulation is aqueous and contains an antisense oligonucleotide, so packaging suppliers must address adsorption, leachables, tungsten or metal contamination, silicone oil exposure and particulate formation.

Potential commercial products include:

• Low-binding glass vials
• Coated or optimized elastomeric stoppers
• Low-particulate aluminum seals
• Integrated container closure systems
• Extractables and leachables packages
• Cold-chain packaging for global distribution

A packaging change can require comparability studies and regulatory review. That raises switching costs and favors suppliers with established qualification data.

What formulation patents protect SPINRAZA?

Spinraza’s commercial protection is primarily associated with nusinersen, antisense oligonucleotide technology, manufacturing and therapeutic-use rights rather than with the small-molecule excipients themselves.

The excipients listed in the FDA label are widely used pharmaceutical ingredients. Sodium chloride, calcium chloride dihydrate, dibasic sodium phosphate and water for injection are unlikely to provide meaningful stand-alone exclusivity. A defensible formulation position would more likely depend on:

• Specific concentration ranges
• Defined pH and osmolality
• Oligonucleotide stability characteristics
• Reduced aggregation or adsorption
• Container compatibility
• Manufacturing controls
• Sterile intrathecal administration
• Dosing regimens and patient populations

The FDA label does not establish patent scope. Patent rights must be assessed through issued claims, prosecution history, assignment records, Orange Book data and relevant litigation filings.

What is the Orange Book status of SPINRAZA?

Spinraza is approved under FDA NDA 209531. Orange Book listings, if any, must be reviewed directly against the current FDA Orange Book database because listed patents and delisting status can change.[2]

For commercial planning, stakeholders should separate four categories:

Protection category	Relevance to excipient opportunity
Active-ingredient or sequence patents	May delay generic or follow-on entry
Manufacturing patents	Can restrict production routes or process design
Formulation patents	May affect alternative excipient systems
Method-of-use patents	May affect label-compliant indications and dosing

An excipient supplier does not necessarily infringe a formulation or manufacturing patent by supplying a compendial ingredient. Risk usually arises at the finished-product manufacturer or licensee level, particularly where a product adopts a claimed concentration range, process step or delivery method.

When does SPINRAZA lose exclusivity?

Spinraza’s effective exclusivity period depends on the interaction of patent expiry, regulatory exclusivity, pediatric extensions, patent-term adjustments and any settlement agreements. FDA approval alone does not determine the date of generic entry.

The relevant U.S. entry pathways include:

• Abbreviated New Drug Application under section 505(j), if the product can be adequately characterized as a generic
• 505(b)(2) application for a modified formulation, presentation or delivery approach
• Biologics-style follow-on analysis is generally not the primary pathway because nusinersen is a chemically synthesized antisense oligonucleotide rather than a protein biologic
• Full or hybrid development for complex oligonucleotide products where bioequivalence is difficult to establish

A competing product could face substantial technical barriers even after key patents expire. Intrathecal administration, oligonucleotide characterization, sterility, impurity control and clinical pharmacology can make a follow-on product more complex than a conventional injectable generic.

What generic entry risks exist for SPINRAZA?

Generic or follow-on entry risk is likely to emerge in stages rather than through immediate substitution.

Stage one: patent and regulatory challenge

A challenger would assess Orange Book listings, submit a Paragraph IV certification where applicable and develop a litigation strategy around sequence, formulation, manufacturing or use claims. The commercial value of a challenge depends on whether the challenger can obtain an early launch opportunity or settlement terms.

Stage two: technical comparability

A follow-on manufacturer would need to show that its product has comparable identity, strength, quality and performance. Critical comparability parameters include:

• Oligonucleotide sequence and chemical modifications
• Purity and impurity profile
• Molecular weight distribution
• pH and osmolality
• Particulate burden
• Sterility and endotoxin
• Container closure performance
• Intrathecal administration suitability

Stage three: institutional adoption

Even after approval, substitution may be slower than for oral generics. Spinraza is administered by healthcare professionals, often through lumbar puncture. Hospitals and specialty centers may retain the originator because of procurement contracts, physician familiarity, patient-support programs and established treatment protocols.

How does SPINRAZA compare with competing SMA therapies?

Spinraza competes with Evrysdi (risdiplam), an oral small-molecule therapy marketed by Roche, and Zolgensma (onasemnogene abeparvovec-xioi), a one-time gene therapy marketed by Novartis.[3-5]

Product	Active modality	Administration	Excipient strategy	Commercial implication
Spinraza	Antisense oligonucleotide	Intrathecal injection	Minimal preservative-free aqueous solution	High sterile and procedural requirements
Evrysdi	Small molecule	Oral liquid or tablet	Oral solution excipient system	Greater formulation and patient-use flexibility
Zolgensma	Gene therapy vector	Intravenous infusion	Biologic vector formulation	Cold-chain, vector stability and specialized manufacturing

Spinraza’s excipient opportunity is more closely tied to sterile injectable infrastructure than to oral formulation technology. Evrysdi creates opportunities in taste masking, suspending systems, dosing devices and multidose preservation. Zolgensma creates opportunities in vector stabilization, low-binding packaging and frozen or refrigerated logistics.

What manufacturing and IP barriers affect SPINRAZA?

The main barriers are not the individual excipients. They are the integrated manufacturing system.

Manufacturing barriers

• Aseptic processing for a preservative-free product
• Oligonucleotide-specific impurity and degradation testing
• Control of adsorption to equipment and packaging
• Intrathecal-grade sterility and endotoxin performance
• Validated vial closure integrity
• Reliable supply of high-purity injectable excipients
• Global batch release and distribution controls

IP barriers

• Sequence and antisense chemistry claims
• Manufacturing-process claims
• Formulation and stability claims
• Dosing and treatment-method claims
• Patent term adjustments and pediatric extensions
• Settlement agreements with potential launch restrictions

An excipient substitution can also create regulatory risk even where no patent issue exists. Changes in buffer composition, ionic strength, pH or container materials may affect stability and require comparability data.

What licensing opportunities exist around SPINRAZA?

The most realistic licensing opportunities are service and technology agreements rather than licenses to the basic excipients.

Potential deal structures include:

• Long-term supply agreements for pharmaceutical-grade calcium chloride
• Dual-source agreements for sodium chloride and phosphate
• Fill-finish contracts with capacity reservations
• Exclusive packaging supply arrangements
• Licensing of low-adsorption container systems
• Technology licenses for oligonucleotide stabilization
• Regional manufacturing and distribution rights
• Co-development of alternative delivery systems

A formulation technology would have greater value if it reduces cold-chain requirements, extends shelf life, lowers particulate risk or enables a more convenient administration method without compromising intrathecal safety.

How strong is the SPINRAZA excipient patent estate?

The excipient-specific patent estate appears structurally weaker than the active-ingredient, antisense-technology and method-of-use estate. The labeled excipients are established pharmaceutical materials, and their generic chemical identities are not likely to provide durable exclusivity.

The stronger commercial protections are more likely to arise from:

• Product-specific formulation ranges
• Stability profiles
• Manufacturing controls
• Container closure combinations
• Use of nusinersen in defined patient groups
• Dosing schedules
• Follow-on delivery technologies

A potential entrant should treat the excipients as enabling components within a broader patent and regulatory system, not as the principal source of exclusivity.

Key Takeaways

• Spinraza is a preservative-free 12 mg/5 mL intrathecal nusinersen solution.
• Its listed excipients are sodium chloride, calcium chloride dihydrate, dibasic sodium phosphate and water for injection.
• The highest-value opportunities are sterile fill-finish, packaging, analytical testing and supply-chain qualification.
• Basic excipient sales face commodity pricing and limited differentiation.
• Formulation changes can create regulatory and comparability burdens even when the replacement excipients are familiar.
• Generic entry is technically more difficult than for a conventional injectable because of antisense characterization and intrathecal administration.
• Spinraza’s meaningful IP risk is more likely to involve nusinersen sequence, manufacturing, formulation ranges and methods of use than the excipients themselves.
• Competing SMA products create different excipient opportunities: oral formulation for Evrysdi and biologic-vector stabilization for Zolgensma.

FAQs

Can sodium chloride used in SPINRAZA be replaced?

A replacement would require formulation, stability, compatibility and regulatory assessment. The replacement must preserve product quality, osmolality, pH and intrathecal safety.

Is SPINRAZA a biologic?

Nusinersen is a chemically synthesized antisense oligonucleotide. Spinraza is regulated as a drug under an FDA NDA rather than as a conventional protein biologic.

Does SPINRAZA require reconstitution?

No. Spinraza is supplied as a ready-to-use sterile solution in a single-dose vial.

Can SPINRAZA be packaged in a prefilled syringe?

A prefilled syringe could improve handling, but it would require assessment of adsorption, extractables, leachables, container closure integrity, dose accuracy and intrathecal administration risk.

Which excipient has the greatest strategic value in SPINRAZA?

The highest strategic value lies in the integrated sterile formulation and packaging system. Calcium chloride and dibasic sodium phosphate are technically important but represent low-volume raw-material opportunities.

References

1. U.S. Food and Drug Administration. (2023). Spinraza (nusinersen) prescribing information. Biogen Inc.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2020). Evrysdi (risdiplam) prescribing information. Genentech USA, Inc.
4. U.S. Food and Drug Administration. (2019). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information. AveXis, Inc.
5. Biogen Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.